This study, published in Frontiers in Oncology, provides a comprehensive 10-year look at how imatinib—the "gold standard" first-generation tyrosine kinase inhibitor (TKI)—performs in a real-world Chinese clinical setting. The researchers confirm that imatinib remains highly effective and safe over the long term, while also demonstrating that many patients can successfully transition to lower doses or even stop treatment entirely (treatment-free remission) without losing control of the disease.
TL;DR
A decade-long study of 237 CML patients in China confirms that frontline imatinib therapy yields excellent survival rates (97.3% transformation-free survival at 10 years). Crucially, the data supports "de-escalation" strategies, showing that patients with stable responses can safely reduce their dosage or attempt treatment-free remission (TFR) in real-world settings.
What Problem Does This Paper Address?
Chronic Myeloid Leukemia (CML) was once a fatal bone marrow cancer. The advent of TKIs like imatinib transformed it into a manageable chronic condition. However, most landmark data (like the IRIS trial) comes from Western populations and highly controlled clinical environments.
In China, imatinib is the primary first-line treatment due to its established efficacy and cost-effectiveness. There is a pressing need for long-term, real-world evidence within the Chinese population to answer three key questions:
- Does imatinib maintain its efficacy over a decade in a general patient population?
- Can patients suffering from side effects safely reduce their dose?
- Is "Treatment-Free Remission" (stopping the drug entirely) a realistic goal for these patients?
Methods
The researchers conducted a retrospective observational study of 237 patients with CML in the chronic phase (CML-CP) treated at Union Hospital in Wuhan between 2011 and 2021.
Key methodological features included:
- Response Monitoring: Regular cytogenetic and molecular testing (BCR-ABL1 mRNA levels) to track disease status.
- Survival Metrics: Evaluation of Transformation-Free Survival (TFS), Event-Free Survival (EFS), and Failure-Free Survival (FFS).
- Dose Reduction Analysis: Comparing a "low-dose" group (300mg or 200mg daily) against the standard 400mg dose in patients who had already achieved a sustained deep molecular response (DMR).
- TFR Assessment: Tracking patients who attempted to discontinue the drug after maintaining DMR for at least two years.
Datasets
The primary dataset consisted of clinical records from 237 CML-CP patients.
- Demographics: Median age of 46; 51.1% male.
- Treatment: 44.3% received imported brand-name imatinib, while 53.2% received domestic generics.
- Follow-up: A median follow-up period of 6.5 years, with some patients tracked for over 10 years.
Key Insights and Ideas
- The "Ceiling" of Imatinib: While second-generation TKIs (like dasatinib) induce faster responses, this study shows that imatinib eventually "catches up." The cumulative Major Molecular Response (MMR) reached 80.4% over the long term, suggesting imatinib remains a powerhouse for frontline therapy.
- Safety of De-escalation: One of the most significant findings is that reducing the dose to 200–300mg (often to manage side effects like neutropenia or edema) did not significantly increase the risk of molecular relapse compared to the standard 400mg dose.
- TFR is Achievable but Selective: While only 5.5% of the total cohort remained in successful treatment-free remission, the study proves the feasibility of this "functional cure" in a real-world Chinese setting. The median time to maintain DMR before stopping was 8.43 years, highlighting that patience is key.
- Generic vs. Brand: Though not the primary focus, the successful outcomes for the 53.2% of patients on domestic generics provide implicit support for the quality of generic imatinib in China.
Key Results
- 10-Year Survival: Transformation-free survival (TFS) was 97.3%, and Event-free survival (EFS) was 87.2%.
- Response Rates: Cumulative Complete Cytogenetic Response (CCyR) was 82.6%, and the Deep Molecular Response (MR4.5) rate was 69.3%.
- Dose Reduction: 21.9% of patients moved to a low-dose regimen. There were no significant differences in 1-year or 2-year molecular relapse-free survival between the standard and low-dose groups.
- Toxicity: No new or late-onset toxicities appeared after years of therapy. The most common severe (Grade 3/4) adverse events were hematological: neutropenia (9.3%) and anemia (7.6%).
Limitations and Future Work
- Retrospective Design: As an observational study, it is subject to selection bias; patients who did well were more likely to remain in the study for 10 years.
- Missing Risk Scores: The authors noted they could not calculate Sokal or ELTS risk scores for all patients at diagnosis due to missing baseline data, which limits the ability to predict who will respond best.
- Sample Size for TFR: The number of patients who attempted to stop the drug (28) and those who successfully stayed off it (13) is relatively small.
Future Work: The authors suggest larger, prospective multicenter studies in China to further refine the criteria for safe dose reduction and to identify better biomarkers for predicting successful treatment-free remission.
Summary updated